BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure
Recruiting
- Conditions
- Congenital Heart DiseaseFontan ProcedureChildrenPrevention of Venous Thromboembolism
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 50
- Registration Number
- NCT06193863
- Locations
- 🇯🇵
Many Locations, Multiple Locations, Japan
A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis
Phase 2
Recruiting
- Conditions
- ThrombolysisSymptomatic Proximal Deep Vein Thrombosis
- Interventions
- Drug: Placebo to BAY3018250
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 255
- Registration Number
- NCT06149520
- Locations
- 🇮🇹
Azienda Unita Locale Socio Sanitaria 2 Marca Trevigiana | Castelfranco Veneto Hospital - Angiologia Department, Castelfranco Veneto, Italy
🇳🇱Radboud University Medical Center | Afdeling Interne Geneeskunde, Nijmegen, Netherlands
🇳🇱Isala, Zwolle, Netherlands
An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
Recruiting
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3000
- Registration Number
- NCT06148935
- Locations
- 🇰🇷
Many Locations, Multiple Locations, Korea, Republic of
A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment
Active, not recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 200
- Registration Number
- NCT06137170
- Locations
- 🇪🇸
Many Locations, Multiple Locations, Spain
A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants
Phase 1
Completed
- Conditions
- Contrast Enhancement in Magnetic Resonance ImagingHealthy Volunteers
- Interventions
- Drug: Gadoquatrane (BAY1747846) 0.03 mmol Gd/kgDrug: Gadoquatrane (BAY1747846) 0.1 mmol Gd/kgDrug: Matching placebo
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT06135181
- Locations
- 🇨🇳
Beijing Hospital, Beijing, China
A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants
Phase 1
Completed
- Conditions
- Contrast Enhancement in Magnetic Resonance ImagingHealthy Volunteers
- Interventions
- Drug: Matching placebo
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 25
- Registration Number
- NCT06125366
- Locations
- 🇯🇵
SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Japan
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
Recruiting
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 300
- Registration Number
- NCT06117891
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸University Of Cincinnati Division Of Hematology Oncology - UC Health System, Cincinnati, Ohio, United States
A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause
Phase 2
Completed
- Conditions
- Sleep Disturbances Associated With Menopause
- Interventions
- Other: Placebo
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 110
- Registration Number
- NCT06112756
- Locations
- 🇩🇪
Siteworks - Zentrum für klinische Studien Hannover, Hannover, Niedersachsen, Germany
🇺🇸MomDoc Women's Health Research | Scottsdale, AZ, Scottsdale, Arizona, United States
🇺🇸Preferred Research Partners, Little Rock, Arkansas, United States
An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions
Completed
- Conditions
- Gadoxetate Sodium-enhanced Magnetic Resonance ImagingMetastatic Pancreatic CancerLiver Metastases
- Interventions
- Procedure: EOB-MRIProcedure: SurgeryProcedure: Open-close Laparotomy
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 39624
- Registration Number
- NCT06106568
- Locations
- 🇯🇵
Many locations, Multiple Locations, Japan
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
Recruiting
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)Visual ImpairmentDiabetic Macula Edema (DME)
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2500
- Registration Number
- NCT06075147
- Locations
- 🇬🇧
Many Locations, Multiple Locations, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath